Safety & Quality Standards
A 2026 health-policy analysis of cross-border CAR-T treatment put it plainly: patients now move faster than institutions, and a therapy is only as good as the follow-up attached to it. These are the standards we hold every case to, in response.
Regulatory framework
Every therapy we coordinate access to is approved for a specific, defined indication by China's National Medical Products Administration (NMPA), the national regulator equivalent to the US FDA or the EU's EMA. Manufacturing occurs at GMP-certified (Good Manufacturing Practice) cell-processing facilities, subject to NMPA inspection. We only coordinate on-label use of approved products for approved indications, and we will tell you explicitly, in writing, if something under discussion would instead be off-label use or participation in a clinical trial.
Our three non-negotiable standards
A written shared-care agreement
Before infusion, the treating hospital, the patient, and a named clinician at home sign an agreement specifying who reviews which tests, who responds to urgent symptoms at key intervals, and who contacts the manufacturer if needed.
Honest, itemized quotations
Every quotation separates therapy, hospitalization, possible intensive care, accommodation and follow-up, with exclusions stated explicitly — never a single bundled number.
A treatment passport that travels with you
Exact product and batch number, medicines given before infusion, complications, and your monitoring schedule, written in a format your home emergency department can use immediately — sent before you land, not after you ask.
Risks we disclose to every patient, every time
- Cytokine release syndrome (CRS) and neurological effects (ICANS), the most common serious acute reactions, typically within the first one to two weeks post-infusion.
- Infection risk from prolonged low blood counts, both from lymphodepleting chemotherapy and the therapy's effect on normal B-cells.
- Long-term monitoring for rare secondary cancers, an area where regulators including the US FDA have asked manufacturers of several CD19/BCMA CAR-T products to track outcomes — which is why our follow-up plans extend for years, not months.
- No guarantee of response. Published trial data shows most appropriately selected patients respond to CD19 and BCMA CAR-T therapy, but not every patient does, and not every response is durable.
Data privacy
Your medical records are transmitted and stored using encrypted channels, shared only with the specific physicians reviewing your case and the treating hospital, and never used for marketing without your separate, explicit consent. See our Privacy Policy for full detail.
What "independent" means here
CellBridge China is a patient-coordination service. We are not a hospital, we do not manufacture or sell any drug or cell therapy product, and we do not receive payment from manufacturers for product selection — your treating physician selects the product and hospital based on your clinical case.